We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rapid progression of prostate cancer in men with a BRCA2 mutation.
- Authors
Narod, S A; Neuhausen, S; Vichodez, G; Armel, S; Lynch, H T; Ghadirian, P; Cummings, S; Olopade, O; Stoppa-Lyonnet, D; Couch, F; Wagner, T; Warner, E; Foulkes, W D; Saal, H; Weitzel, J; Tulman, A; Poll, A; Nam, R; Sun, P; Danquah, Jessica; Domchek, Susan; Tung, Nadine; Ainsworth, Peter; Horsman, Douglas; Kim-Sing, Charmaine; Maugard, Christine; Eisen, Andrea; Daly, Mary; McKinnon, Wendy; Wood, Marie; Isaacs, Claudine; Gilchrist, Dawna; Karlan, Beth; Nedelcu, Raluca; Meschino, Wendy; Garber, Judy; Pasini, Barbara; Manoukian, Siranoush; Bellati, Christina; Hereditary Breast Cancer Study Group
- Abstract
Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.
- Publication
British journal of cancer, 2008, Vol 99, Issue 2, p371
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/sj.bjc.6604453